…
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
| Income before tax | -463.27M | -128.76M | -50.65M | -51.24M | -56.44M |
| Net income | -459.65M | -123.12M | -50.65M | -51.37M | -56.50M |
| Selling general administrative | 81.21M | 99.11M | 31.58M | 26.15M | 19.66M |
| Selling and marketing expenses | 99.11M | 86.77M | 33.71M | 30.05M | 23.46M |
| Gross profit | 164.24M | 141.00M | 76.69M | 58.82M | 34.24M |
| Reconciled depreciation | 46.38M | 42.61M | 8.21M | 8.52M | 9.39M |
| Ebit | 135.90M | -171.14M | -46.78M | -48.20M | -54.07M |
| Ebitda | 182.27M | -128.67M | -38.71M | -39.80M | -44.68M |
| Depreciation and amortization | 46.38M | 42.48M | 8.06M | 8.41M | 9.39M |
| Non operating income net other | -0.01M | -0.13M | -0.15M | - | - |
| Operating income | 135.90M | -171.14M | -46.78M | -48.20M | -53.98M |
| Other operating expenses | 526.95M | 481.16M | 217.13M | 180.71M | 148.79M |
| Interest expense | 0.26M | 2.90M | 3.72M | 2.92M | 2.37M |
| Tax provision | -3.62M | -5.64M | 0.00M | 0.13M | 0.06M |
| Interest income | 0.26M | - | - | - | 2.37M |
| Net interest income | 0.26M | -2.90M | -3.72M | -2.92M | -2.37M |
| Non recurring | 299.70M | - | - | - | - |
| Income tax expense | -3.62M | -5.64M | 0.00M | 0.13M | 0.06M |
| Total revenue | 363.14M | 310.02M | 170.36M | 132.51M | 94.81M |
| Total operating expenses | 328.05M | 312.14M | 123.46M | 107.03M | 88.22M |
| Cost of revenue | 198.91M | 169.02M | 93.67M | 73.69M | 60.57M |
| Total other income expense net | -599.17M | 42.38M | -3.87M | -3.03M | -0.09M |
| Net income from continuing ops | -459.65M | -123.12M | -50.65M | -51.37M | -56.50M |
| Net income applicable to common shares | -459.65M | -123.12M | -50.65M | -51.37M | -56.50M |
| Breakdown | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 |
| Total assets | 788.15M | 903.07M | 1285.53M | 475.51M | 124.41M |
| Intangible assets | 165.41M | 203.20M | 244.69M | 0.60M | 2.05M |
| Other current assets | 15.81M | 14.15M | 9.47M | 5.96M | 12.94M |
| Total liab | 342.69M | 429.28M | 429.74M | 84.66M | 148.19M |
| Total stockholder equity | 445.46M | 473.79M | 855.79M | 390.85M | -23.77M |
| Deferred long term liab | - | - | 4.56M | 5.19M | 3.88M |
| Other current liab | 52.24M | 51.09M | 50.19M | 40.79M | 31.09M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -1054.10M | -954.29M | -494.64M | -371.52M | -320.87M |
| Other liab | - | - | 4.83M | 5.59M | 5.92M |
| Good will | 278.19M | 278.19M | 577.90M | 4.01M | 4.01M |
| Other assets | 0.00M | - | 8.88M | 7.68M | 4.62M |
| Cash | 185.72M | 321.08M | 365.85M | 433.88M | 84.32M |
| Total current liabilities | 107.85M | 119.41M | 111.75M | 79.08M | 69.96M |
| Current deferred revenue | 34.77M | 50.88M | 47.14M | 30.89M | 33.59M |
| Net debt | 55.93M | -4.29M | -46.11M | -433.88M | -12.01M |
| Short term debt | 7.09M | 7.28M | 6.59M | - | - |
| Short long term debt | 0.44M | 0.60M | 0.60M | - | - |
| Short long term debt total | 241.65M | 316.80M | 319.74M | - | 72.31M |
| Other stockholder equity | 1499.60M | 1428.07M | 1350.43M | 762.36M | 297.09M |
| Property plant equipment | - | 14.76M | 11.80M | 9.23M | 13.62M |
| Total current assets | 280.54M | 365.95M | 409.14M | 453.98M | 100.10M |
| Net tangible assets | - | -7.61M | 33.21M | 386.23M | -262.86M |
| Short term investments | 51.31M | - | - | - | - |
| Net receivables | 27.70M | 26.70M | 30.80M | 11.84M | 1.19M |
| Long term debt | 208.48M | 282.32M | 280.67M | - | 72.31M |
| Inventory | 0.00M | 4.02M | 3.02M | 2.30M | 1.65M |
| Accounts payable | 13.75M | 10.15M | 7.84M | 7.39M | 5.27M |
| Accumulated other comprehensive income | -0.05M | - | - | -475.51M | -50.61M |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings total equity | - | -954.29M | -494.64M | -371.52M | - |
| Non currrent assets other | 16.53M | 11.44M | 8.88M | 7.68M | 4.62M |
| Non current assets total | 507.61M | 537.12M | 876.39M | 21.53M | 24.31M |
| Capital lease obligations | 32.73M | 34.47M | 39.08M | - | - |
| Long term debt total | - | 282.32M | 280.67M | - | - |
| Breakdown | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 | 2019-02-28 |
| Investments | -7.23M | -263.61M | -2.42M | -3.52M | -3.12M |
| Change to liabilities | 4.92M | 9.57M | 16.65M | 8.12M | 17.71M |
| Total cashflows from investing activities | -7.23M | -263.61M | -2.42M | -3.52M | -3.12M |
| Net borrowings | - | 279.13M | -22.75M | 1.66M | -2.10M |
| Total cash from financing activities | 3.16M | 257.93M | 428.38M | 28.22M | 48.83M |
| Change to operating activities | -10.01M | -10.07M | 14.08M | -12.84M | -1.18M |
| Net income | -459.65M | -123.12M | -50.65M | -51.37M | -56.50M |
| Change in cash | -44.77M | -68.03M | 400.73M | -9.55M | 29.17M |
| Begin period cash flow | 365.85M | 433.88M | 33.16M | 42.70M | 13.53M |
| End period cash flow | 321.08M | 365.85M | 433.88M | 33.16M | 42.70M |
| Total cash from operating activities | -40.70M | -62.35M | -25.23M | -34.25M | -16.55M |
| Issuance of capital stock | 0.00M | 0.00M | 439.41M | 19.94M | 49.93M |
| Depreciation | 46.38M | 42.61M | 8.21M | 8.52M | 9.39M |
| Other cashflows from investing activities | -5.12M | -261.09M | -0.43M | -0.06M | -0.06M |
| Change to inventory | - | - | 7.66M | - | - |
| Change to account receivables | 4.11M | -11.83M | -10.65M | -0.68M | 6.52M |
| Sale purchase of stock | 4.99M | 13.24M | 451.14M | - | 50.94M |
| Other cashflows from financing activities | 3.16M | -189.29M | 62.89M | -3.52M | 53.94M |
| Change to netincome | 374.01M | 29.20M | 11.83M | 13.02M | 6.71M |
| Capital expenditures | 7.23M | 3.62M | 2.37M | 3.31M | 3.12M |
| Cash flows other operating | -6.36M | -20.60M | -11.27M | - | - |
| Cash and cash equivalents changes | -44.77M | -68.03M | 400.73M | - | - |
| Change in working capital | -1.14M | -7.84M | 3.72M | -5.40M | 23.84M |
| Stock based compensation | 72.64M | 72.94M | 9.58M | 6.00M | 5.72M |
| Other non cash items | 305.06M | -40.80M | 3.91M | 1.82M | 0.42M |
| Free cash flow | -47.93M | -65.97M | -27.60M | -37.56M | -19.67M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems Inc Class A |
-10.86 3.63% |
288.42 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
- -% |
136.55 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-1.27 1.96% |
63.49 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.04 0.71% |
5.56 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
| Name | Title | Year Born |
|---|---|---|
| Mr. Rajeev Singh | Chairman & CEO | 1968 |
| Mr. Robert Cavanaugh | Pres | 1969 |
| Mr. Stephen H. Barnes CPA | CFO & Treasurer | 1972 |
| Mr. Michael W. Hilton | Chief Innovation Officer | 1965 |
| Mr. Todd Friedman | Sr. VP of Investor Relations | NA |
| Mr. Richard Eskew | EVP, Gen. Counsel, CCO & Sec. | NA |
| Ms. Carolina Lobo | Chief Marketing Officer | NA |
| Ms. Kristen Keating Weeks | VP of Strategy, Corp. Devel. & Partnerships | NA |
| Ms. Jennifer Hanson | Exec. VP of People and Culture & Chief HR Officer | NA |
| Mr. Todd Clardy | Exec. VP & GM of Mid-Market Bus. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.